Teva Pharmaceutical Industries Ltd. ADR (TEVA) News
Filter TEVA News Items
TEVA News Results
|Loading, please wait...|
TEVA News Highlights
- TEVA's 30 day story count now stands at 29.
- Over the past 23 days, the trend for TEVA's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- The most mentioned tickers in articles about TEVA are DRUG, PAY and TOP.
Latest TEVA News From Around the Web
Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.
Here is your weekly roundup of the biggest news out of hedge funds and company top brass, all first covered on InvestingPro+.
As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be the middlemen negotiating and dispensing the drugs such as Cigna and CVS.
Many seniors are all too familiar with the name Teva Pharmaceutical when they look at their medications as they refill their pill containers each week. Teva is known primarily as a manufacturer of generic drugs. Trading volume in TEVA looks like it has increased since May.
Here are the most active equity options for midday.
The Dow Jones Industrial Average is up 271 points midday, while the Nasdaq Composite and S&P 500 Index are firmly higher as well.
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and AbbVie Inc (NYSE: ABBV) have finalized the settlement's terms worth over $6.6 billion to resolve several lawsuits by U.S. state and local governments over the marketing of opioid painkillers. Under the deals, first announced in July, Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion. Reuters reported that the final amounts of settlements would depend on how many state and lo
Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of an expanding market. More than 55 brand-name blockbuster biologic drugs, each with peak annual sales above $1 billion, are due to come off patent by the end of the decade, according to industry estimates. Executives from Teva and Sandoz said they are targeting top-selling biologics such as Humira, AbbVie Inc’s top-selling arthritis drug, which came off-patent in Europe and is due to come off-patent in the U.S. next year.
Teva Pharmaceutical Industries Ltd and AbbVie Inc have finalized the terms of settlements worth more than $6.6 billion to resolve thousands of lawsuits by U.S. state and local governments over the marketing of opioid painkillers, the companies and lawyers for the governments said Tuesday. Under the deals, first announced in July, Israel-based Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion.
Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.
TEL AVIV, Israel & PARSIPPANY, N.J., November 22, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the company has finalized the documentation of its proposed nationwide opioid settlement with both the working group of States’ Attorneys General and the Multi-District Litigation Plaintiffs’ Executive Committee. Allergan has also finalized its settlement terms. As announced during the Company’s third quarter earnings ca